Adalvo is pleased to announce the addition of Riociguat 0.5mg, 1mg, 1.5mg, 2mg & 2.5mg Film Coated Tablets to our product Portfolio.
Our product is being developed in collaboration with one of our strategic partners, based on the reference brand Adempas and is indicated in the treatment of pulmonary arterial hypertension (PAH).
The brand sold approximately $320mio globally in 2021 with Global 3Y CAGR at 12%, according to IQVIA.
With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and first to launch in all major markets.
Adalvo is working on several interesting Cardiovascular projects, as depicted below. The addition of Riociguat further strengthens this domain and highlights our ability to offer differentiated, value-added products to our partners.
